DGX News - Candlesense

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

SECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will sp...

What macroeconomic or healthcare policy factors discussed at the conference could influence Quest Diagnostics' long‑term growth trajectory? How does the current valuation of DGX compare to its historical averages, and could the conference provide catalysts for a re-rating? Is there any indication of capital allocation plans, such as share buybacks or dividend adjustments, that could move the stock?

Conference

6 days ago

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash divid...

Could the dividend announcement trigger any changes in the stock's options implied volatility or open interest? What is the payout ratio based on the latest earnings, and is it sustainable? How might this dividend declaration impact institutional investors' holding strategies for DGX?

Dividends

8 days ago

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators ...

If the trials demonstrate clinical benefit, what is the expected timeline for market launch and adoption by oncologists? What regulatory pathways (e.g., Breakthrough Device, Fast Track) is Haystack pursuing for this technology, and what are the associated risks? How might the trial outcomes influence the pricing and reimbursement landscape for MRD‑guided treatments?

Clinical trials

15 days ago